Lancet Global Health: Study on prognostic differences between Maori, Pacific and European type 2 diabetes patients in New Zealand.

In Oceania, the impact of type 2 diabetes on indigenous and non-European populations is not well studied.
long-term trends in clinical outcomes for specific causes of type 2 diabetes between Maori, Pacific and Europeans in New Zealand are unclear.
recently looked at differences in mortality and hospitalization rates among Maori, Pacific and European type 2 diabetes patients in Auckland, New Zealand.
In this retrospective, population-based longitudinal queue study, type 2 diabetes patients (35-84 years old) registered between January 1, 1994 and July 31, 2018 participated in the Diabetes Care Support Service (DCSS) in Oakland, excluding people with type 1 diabetes, prediabetes and gestational diabetes.
linked data from DCS to the National Death Registration, Hospital Hospitalization, Drug Claims and Socioeconomic Status Database, follow-up to the patient's death or July 31, 2018.
end-of-life events in the study included clinical events (all-cause mortality, cardiovascular mortality, cancer mortality, cardiovascular hospitalization, cancer hospitalization, and end-stage renal hospitalization).
total includes 45,072 people with type 2 diabetes, of whom 21,936 were women, with an average age of 56.7 years and an average follow-up of 9.7 years, of whom 37.2 per cent were of European descent, 15.7 per cent were Maori and 26.7 per cent were of Pacific descent.
three ethnic groups have similar time-varying trends: mortality rates for people with type 2 diabetes have declined and hospitalizations have increased, but admission rates for Maori and Pacific people have consistently been higher than among Europeans.
the total cause mortality rate (1.96), cardiovascular mortality (1.93) and tumor mortality (1.64) were higher than that of Europeans.
20 years, the prognostics of type 2 diabetes among Maori and Pacific people in New Zealand have generally been worse than those of European descent.
.